Dr. Anne Covey on Locoregional Therapy in Hepatocellular Carcinoma
Anne Covey, MD, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant.
Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant. Covey says this group of patients is around 80% of those diagnosed with HCC, and the most common form of therapy is locoregional treatment, or therapy targeted to the liver.
Covey says some beneficial locoregional therapies offered to patients with HCC are bland embolization, chemoembolization, radioembolization, embolization with drug-eluding beads, and ablation.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer
December 19th 2024During a Case-Based Roundtable® event, Ramez N. Eskander, MD, and participants discussed first and second-line therapy decisions for a patient with PD-L1–positive cervical cancer in the frontline metastatic setting.
Read More
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More
